Board of Directors
Wayne B. Weisman
Chairman of the Board
Wayne B. Weisman has been a director of the company and the chairman of our board since 2008. Since 2007, Weisman has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns 33.6% of our outstanding stock as of April 1, 2016. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife.
He has also led the activities of SCP Private Equity Partners II, L.P., a venture capital fund of which he and Churchill are principals in the life sciences area. His activities include investments in the United States and Israel. He has also led several other technology investments for SCP Private Equity Partners II, L.P. He has been a member of the investment committee of the Vitalife Life Sciences funds since their inception in 2002 and has worked closely with these funds since then.
Weisman has been a member of the board of directors of CIP Capital L.P., a small business investment company licensed by the U.S. Small Business Administration since its inception in 1991. From 1992 to 1994, Weisman was executive vice president and member of the board of directors of a public drug delivery technology company. In addition, he also operated a management and financial advisory firm focusing on the reorganization and turnaround of troubled companies and began his career practicing reorganization law at a large Philadelphia law firm.
Weisman possesses extensive experience in venture capital investing, particularly in the life sciences area. Weisman serves on the board of ReWalk Robotics Ltd. and on a number of private company boards including the boards of DIR Technologies, Endospan Ltd., Ivenix, LLC, and Echo360, Inc. He is the chairman of the boards of trustees of Young Scholars School, Young Scholars Frederick Douglass, and Young Scholars Kenderton. He is also an advisory board member of the Philadelphia-Israel Chamber of Commerce and Mid-Atlantic Diamond Ventures, the venture forum of Temple University. Weisman holds a B.A. from the University of Pennsylvania, and a J.D. from the University of Michigan Law School.
As a long time director of our company, Weisman’s extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise in developing, financing, and providing strong executive leadership to numerous growing life science companies contributed to our board’s conclusion that he should serve as a director of our company.
William L. Ashton
William L. Ashton has been a director of the company since 2009. Since the beginning of 2013, Ashton has been a principal at Harrison Consulting Group, Inc., a privately held biopharmaceutical consulting firm. From August 2009 to June 2013, Ashton was the senior vice president of external affairs reporting to the president and an assistant professor at the University of the Sciences in Philadelphia, Pennsylvania. From August 2005 to August 2009, Ashton was the founding dean of the Mayes College of Healthcare Business and Policy.
Ashton has 29 years of experience in the biopharmaceutical industry. From 1989 to 2005, Ashton held a number of positions at Amgen Inc., a biotechnology company, including vice president of U.S. sales and vice president of commercial and government affairs. Ashton currently serves on the boards of directors of Galena Biopharma, Inc. and Sucampo Pharmaceuticals, Inc. He is also a member of the board of directors of the National Osteoporosis Foundation and Friends of the National Library of Medicine at the National Institutes of Health. Ashton holds a B.S. in education, from the California University of Pennsylvania and an M.A. in education from the University of Pittsburgh.
Ashton’s extensive experience with pharmaceutical and biological products’ commercialization and reimbursement issues, his past advisory role during the early years of Auxilium, as well as his experience as a board member of privately held companies and his scientific expertise contributed to our board’s conclusion that he should serve as a director of our company.
Michael Berelowitz, M.D.
Michael Berelowitz was elected to our board in March 2014 upon the consummation of our IPO. Since 2011, Berelowitz has served as a biopharmaceutical consultant. From 2009 to 2011, Berelowitz was senior vice president and head of clinical development and medical affairs in the specialty care business unit at Pfizer, Inc., a pharmaceutical company. From 1996 to 2009, he held various other roles at Pfizer, Inc., beginning as a medical director in the diabetes clinical research team and then assuming positions of increasing responsibility.
Prior to that, Berelowitz spent a number of years in academia. Berelowitz also serves on the board of directors of Oramed Pharmaceuticals Inc. Among his public activities, Berelowitz has served on the board of directors of the American Diabetes Association and the Clinical Initiatives Committee of the Endocrine Society, and has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism and Endocrinology, Reviews in Endocrine and Metabolic Disorders, and Clinical Diabetes.
Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes, and metabolic disorders. Berelowitz holds adjunct appointments as professor of medicine in the divisions of endocrinology and metabolism at SUNY Stony Brook and Mt. Sinai School of Medicine in New York. Berelowitz’s years of experience in management roles in the pharmaceuticals industry, as well as his vast skill and expertise in the fields of endocrinology and diabetes, contributed to our Board’s conclusion that he should serve as a director of our company.
Winston J. Churchill
Winston J. Churchill has been a director of the company since 2008. Since 2007, Churchill has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns 33.6% of our outstanding stock as of April 1, 2016. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife.
Churchill has also served since 1993 as the president of CIP Capital Management, Inc., the general partner of CIP Capital, L.P., an SBA-licensed private equity fund. Prior to that, Churchill was a managing partner of Bradford Associates, which managed private equity funds on behalf of Bessemer Securities Corporation and Bessemer Trust Company.
From 1967 to 1983, Churchill practiced law at the Philadelphia firm of Saul Ewing, LLP, where he served as chairman of the banking and financial institutions department, chairman of the finance committee, and was a member of the executive committee. Churchill is a director of Griffin Land & Nurseries, Inc., Innovative Solutions and Support, Inc., Amkor Technology, Inc., and various SCP Vitalife portfolio companies. In addition, he serves as a director on the boards of a number of charities and as a trustee of educational institutions including the Gesu School and Scholar Academies and is a trustee fellow of Fordham University.
From 1989 to 1993, Churchill served as chairman of the finance committee of the Pennsylvania Public School Employees’ Retirement System. He was awarded a B.S. in physics, summa cum laude, from Fordham University, followed by an M.A. in economics from Oxford University, where he studied as a Rhodes Scholar, and a J.D. from Yale Law School.
As a longtime director of our company, Churchill’s extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise in developing, financing, and providing strong executive leadership to numerous growing life science companies contributed to our Board’s conclusion that he should serve as a director of our company.
President and Chief Executive Officer
Gerri Henwood has served as our president and chief executive officer and a director of the company since our inception in 2008. Henwood also serves as chief executive officer and a director of Baudax Bio.
From 2006 to 2013, Henwood served as the president of Malvern Consulting Group (MCG), a pharmaceutical incubator and consulting firm. Henwood continues to spend a very small portion of her time engaged in the provision of consulting services for MCG to other companies, including those engaged in the development and commercialization of other pharmaceutical products.
From 1999 to 2006, Henwood was the president and chief executive officer of Auxilium Pharmaceuticals, a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Henwood was the founder and chief executive officer of IBAH, a contract research organization. IBAH reached a net revenue level of $150 million as a NASDAQ-traded company before being acquired by Omnicare in 1998.
Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline, in the pharmaceutical management program. She rose through the ranks to be a brand manager, then the head of regulatory and medical affairs for the U.S. business and then to the position of group director, marketing in the international pharmaceutical division.
Since May 2015, Henwood has served on the board of directors of Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company, where she also serves on the compensation committee. She is also on the board of two private companies and previously served on the board of directors of Alkermes, Inc., and its successor company, Alkermes plc, a global biopharmaceutical company, from 2003 to March 2015. Henwood holds a B.S. in biology from Neumann University.
As our founder and having served as a director since our inception, Henwood provides extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise born of developing, financing, and providing strong executive leadership to numerous biopharmaceutical companies. Combined with Henwood’s strong background in clinical and product development and substantial knowledge of the pharmaceutical industry, these qualities contributed to our Board’s conclusion that she should serve as a director of our company.
In his current roles as senior vice president of finance and chief financial officer of Impax Laboratories, Reasons’ responsibilities span accounting, financial planning and analysis, business development and investor relations, and corporate communications. Prior to joining Impax in 2012, Reasons held positions of increasing responsibility at Cephalon, Inc., where he successfully navigated acquisition by Teva Pharmaceutical Industries Ltd. for eight billion dollars. He previously served in a number of financial leadership roles at E.I. du Pont de Nemours and Company and PricewaterhouseCoopers LLP, ranging from corporate accounting, external reporting and audit, and business advisory services.
Reasons earned a bachelor’s degree in accounting from Pennsylvania State University and an MBA from Widener University. He is a certified public accountant.